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Original Study

Tumor Heterogeneity as a Predictor of Response
to Neoadjuvant Chemotherapy in Locally
Advanced Rectal Cancer
Alissa Greenbaum,1 David R. Martin,2 Thèrése Bocklage,4 Ji-Hyun Lee,5
Scott A. Ness,3,6 Ashwani Rajput1,6
Abstract
A standard therapy for locally advanced cancers includes neoadjuvant chemoradiation; however, currently
there is no way of knowing which patients have disease that will respond to such therapy. We analyzed 21
pretreatment rectal cancer biopsy samples and found a positive correlation of the response to therapy with a
quantitative mutant-allele tumor heterogeneity (MATH) score. This next-generation sequencing derived score
may serve as a biomarker for response to therapy.
Background: Neoadjuvant chemoradiotherapy (nCRT) is the standard of care for locally advanced adenocarcinoma of
the rectum, but it is currently unknown which patients have disease that will respond. This study tested the correlation
between response to nCRT and intratumoral heterogeneity using next-generation sequencing assays. Patients and
Methods: DNA was extracted from formalin-ﬁxed, parafﬁn-embedded biopsy samples from a cohort of patients with
locally advanced rectal adenocarcinoma (T3/4 or N1/2 disease) who received nCRT. High read-depth sequencing of
> 400 cancer-relevant genes was performed. Tumor mutations and variant allele frequencies were used to calculate
mutant-allele tumor heterogeneity (MATH) scores as measures of intratumoral heterogeneity. Response to nCRT was
pathologically scored after surgical resection. Results: Biopsy samples from 21 patient tumors were analyzed. Eight
patients had disease noted to have complete response, 2 moderate, 4 minimal, and 7 poor. Higher MATH scores
correlated with poorer response to treatment, demonstrating signiﬁcantly increased tumor heterogeneity compared to
complete response (P ¼ .039). Conclusion: The application of MATH scores as a measure of tumor heterogeneity may
provide a useful biomarker for treatment response in locally advanced rectal cancer.
Clinical Colorectal Cancer, Vol. 18, No. 2, 102-9 ª 2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Bioinformatics, Colorectal cancer, Personalized medicine, Targeted sequencing, Translational research

Introduction
Colorectal cancer (CRC) is the third most common and lethal
cancer in the United States. Rectal cancers account for over one
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third of CRC cases, with approximately 39,000 new cases diagnosed
each year.1 Treatment of locally advanced rectal cancer is different
from equivalent-stage colon cancer. Neoadjuvant chemoradiotherapy (nCRT) became the standard of care for locally
advanced disease after a number of landmark randomized controlled
trials found nCRT decreased rates of local tumor recurrence,
increased rates of sphincter preservation, and decreased both acute
and long-term treatment toxicity.2-5 Since 2003, nCRT has been
rapidly adopted and is now extensively used.6 However, the disease
demonstrates a spectrum of response to nCRT, ranging from
complete to poor or no response. Complete response is associated
with decreased local recurrence and improved overall survival
(OS),7-9 while poor response is associated with worse outcomes.
Studies have explored mechanisms to explain resistance to
nCRT,10,11 but no biomarker or single somatic mutation is

1533-0028/ª 2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.clcc.2019.02.003

routinely used to predict which patients have disease that will
respond to nCRT.
Intratumoral heterogeneity (ITH) has been proposed to be a
mechanism of resistance to both chemotherapy and radiotherapy.
Neoplastic cells are thought to proliferate from a singular common
ancestor.12,13 Tumor cells can undergo additional sequential mutations, resulting in subclones within the same tumor. The presence
of ITH correlates with more rapid cell proliferation, increased
metastasis, resistance to therapy,14 and worse clinical outcomes.
Although ITH is studied in research laboratories, a reproducible
method to quantify ITH in the clinical setting is not available.
The mutant-allele tumor heterogeneity (MATH) score is a novel
next-generation sequencing method to quantitatively measure
ITH.15 The MATH score is the width of the distribution of
mutant-allele fractions among tumor loci. A locus that mutated
early in the clonal evolution of the tumor will have a high mutantallele fraction, while later, lower frequency loci mutations demonstrate a lower mutant-allele fraction.16 In head and neck squamouscell carcinoma, higher MATH scores, and therefore increased ITH,
correlate with shorter OS and worse clinical outcomes.16 We previously showed that higher MATH scores correlated with worse
outcome in colon cancer.17 One previous study applied MATH
scores speciﬁcally to rectal cancer, demonstrating highly variable
degrees of tumor heterogeneity in 6 tumors.18 However, the correlation of MATH scores to clinical treatment or outcomes in rectal
cancer is unknown.
The purpose of this study was to determine if MATH scores can
predict response to nCRT in locally advanced rectal
adenocarcinoma.

Patients and Methods
Twenty-three patients with locally advanced rectal cancer who
underwent surgical resection of their tumors after nCRT were
identiﬁed in a prospective database. Locally advanced tumors were
deﬁned as American Joint Commission on Cancer Staging, 7th
edition, T3 or T4 tumors, node-positive (N1/N2) or T2 disease,
with the possibility of sphincter-sparing surgery.19 After institutional review board approval, formalin-ﬁxed, parafﬁn-embedded
blocks of rectal pretreatment tumor biopsy samples were obtained.
Disease was categorized according to nCRT response, as described
by histologic neoinduced regression in the surgical pathologic
specimen (complete 0, minimal þ1, moderate þ2, poor þ3) after
surgical resection. Pretreatment rectal biopsy samples were used for
patient DNA analysis.
DNA was extracted using standard techniques. Samples were
analyzed as previously described17 using the Ion AmpliSeq
Comprehensive Cancer panel assay, which targets more than 400
cancer-relevant genes. Sequencing was performed on the Ion Proton
instrument as described by the manufacturer (Thermo Fisher Scientiﬁc, Waltham, MA), generating average read depths of > 1200
across the targeted regions. As a quality control, only samples that
yielded > 500 average coverage for all 4 multiplexed primer pools
were used for downstream analyses. Variants were called by the
Torrent Server Variant Caller (versions 4.21, 4.421, 4.607, or
5.021, with interchangeable results). The resulting variant caller
format (VCF) ﬁles were compared using customized bioinformatics
scripts, as described previously.17 Analyses were limited to single

nucleotide variants (no indels) with a read depth greater than 100
and at least 5 reads in each direction.
Variant allele frequencies (VAF) were calculated as the ratio of
alternate allele observations to the read depth at each position. The
MATH score is calculated as 100  (median absolute deviation/
median of VAF). It describes the ratio of the width of the data to the
center of the distribution—effectively a score describing the spread
in the data. We applied the MATH score12 to quantify the tumor
heterogeneity in our rectal tumor samples, as well as a modiﬁcation
to include both tumor and germline heterozygous (genotype 0/1)
variants with VAF between 0.05 and 0.75. The comparisons of
MATH score between response categories were conducted using
Student t test statistics after checking the required assumptions of
the distribution and equal variance. P < .05 was considered statistically signiﬁcant.

Results
Targeted next-generation DNA sequencing was used to identify
the somatic tumor variants in a cohort of 23 retrospective rectal
cancer biopsy samples that included disease with response to nCRT
treatment that was judged to be complete, moderate, minimal, or
poor (Table 1). Two samples failed to pass quality-control criteria,
so results from 21 samples were used for analyses.
Because no samples of normal tissue were available for comparison, we identiﬁed tumor mutations on the basis of their exclusion
from databases of common germ-line polymorphisms (dbSNP 137),
with VAF below 0.50. The most common mutations that were also
listed in the Catalog of Somatic Mutations in Cancer (COSMIC)
(PMID 27899578) are shown in Figure 1A. Most common mutations were in the APC, TP53, and KRAS genes, which is similar
but not identical to the mutations most commonly observed by
others.20 The differences could suggest alternative genetic or environmental mechanisms in our cohort of patients from New Mexico.
Figure 1B shows a plot of the observed VAF for each of the
COSMIC mutations shown in Figure 1A. Some mutations (eg,
APC, KMT2C, KRAS, TP53) were observed in a broad range of
allele frequencies in different tumors, suggesting that these mutations were acquired early in the evolution of the tumors. However,
many of the mutations that occurred less frequently (eg, EGFR,
FBXW7, LIFR, MSH6) were only observed at low allele frequencies,
suggesting that they were acquired later and were only present in a
subset of tumor cells.
The correlation between the presence of speciﬁc mutations with
either good or poor response to nCRT treatment was attempted.
Figure 2 shows a heat map indicating the presence of COSMIC
mutations in all samples, which were sorted by either complete or
moderate response to nCRT, and minimal or poor response. There
was no correlation between response and either the presence of
speciﬁc mutations or the number of acquired mutations. For
example, acquired mutations in APC, KRAS, or TP53 were observed
in samples from both groups. Thus, there appears to be no simple
way of predicting response to nCRT solely on the basis of the use of
targeted gene panel sequencing in these types of rectal cancer
samples.
We next determined whether quantitative traits in the sequencing
information could be used to gain additional insight into the
biology of response to nCRT. We previously showed that the
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Table 1 Characteristics of Rectal Cancer Patient Samples
Sample No.
06
08
09
10
30
43
45
47
16
17
12
13
14
15
20
21
36
40
44
46
48

Response

Sex

APC Mutation

KRAS Mutation

TP53 Mutation

MATH Score

Complete
Complete
Complete
Complete
Complete
Complete
Complete
Complete
Moderate
Moderate
Minimal
Minimal
Minimal
Minimal
Poor
Poor
Poor
Poor
Poor
Poor
Poor

F
M
M
M
F
F
F
F
M
F
F
F
M
M
F
F
U
M
U
U
M

Yes
No
Yes
No
Yes
No
No
No
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Yes

No
No
No
Yes
No
No
No
No
No
Yes
No
No
No
Yes
No
No
No
No
No
No
No

No
Yes
No
Yes
No
No
No
No
No
No
No
No
Yes
No
Yes
No
No
No
No
No
No

11.8
17.24
11.06
10.89
15.64
12.73
7.88
14.4
6.62
19.84
8.62
25.23
28.69
15.35
26.67
19.75
13.26
13.55
27.95
14.31
17.05

Abbreviations: MATH ¼ mutant-allele tumor heterogeneity; U ¼ sex information unavailable or not provided.

MATH score as a measure of tumor heterogeneity correlated with
tumor stage in colon cancer.17 We tested whether the MATH score
could be used as a measure of tumor heterogeneity in rectal cancers.
Figure 3 compares the distribution of VAF. Sample 16 shows peaks
of allele frequencies at 0.5 and 1.0, which are the heterozygous and
homozygous variants, with very few somatic mutations at other
frequencies. In contrast, sample 44 shows a broad distribution of
allele frequencies and has a much higher MATH score of 27.95,
compared to 6.62 for sample 16. Thus, the higher MATH score
quantiﬁes the spread in the VAF observed in sample 44, which
reﬂects increased tumor heterogeneity.
Next, we tested whether the MATH scores correlated with
response to nCRT. As shown in Figure 4A, the samples from patients whose disease had complete response to nCRT had signiﬁcantly (P ¼ .039) lower MATH scores than samples from patients
with disease that had poor response to nCRT. A similar difference
was observed when comparing complete response to samples in all
other categories (moderate, minimal, or poor, P ¼ .026; Figure 4B)
or when comparing complete þ moderate response to minimal þ
poor response (P ¼ .02; Figure 4C). In contrast, there was no
difference in MATH scores when comparing samples that did or did
not harbor mutations in APC (Figure 4D) or other common mutations (data not shown).

Discussion
Preoperative nCRT is the standard of care for locally advanced
rectal adenocarcinoma. MATH scores, a novel bioinformatics tool
allowing quantitative measurement of tumor genetic heterogeneity,
appears to have relevance in the study of rectal cancer. We observed
higher MATH scores, and thus increased tumor genetic
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heterogeneity, to be associated with poorer response to nCRT.
Although these results will need to be validated in a larger group of
samples, it appears that measures of tumor heterogeneity such as the
MATH score have the potential to predict treatment response.
Some studies examining biomarkers to predict nCRT response in
rectal cancer have been promising; others have presented contradictory results. In 2001, Ki-67 expression was found to correlate
with nCRT response, with a higher Ki-67 labeling index seen in
patients with complete response.10 In contrast, a study in 2008
demonstrated that lower Ki-67 expression was associated with
higher level of tumor regression.11 Increased expression of epidermal
growth factor receptor (EGFR) and p21 have been observed in
tumors with poor nCRT response,21,22 while high thymidylate
synthase levels and lower pretreatment DNA methylation are
associated with higher response rates.23 These studies suggest that a
number of molecular markers may predict nCRT response,
although conﬁrmatory studies are ongoing, and their routine use in
clinical practice is currently unavailable.
Although the effect of tumor heterogeneity on response to
nCRT in rectal cancer is unknown, genetic heterogeneity is
thought to be a major contributor to monoclonal antibody
treatment resistance in CRC. A number of factors may explain
how increased tumor heterogeneity contributes to treatment
resistance in cancer. A tumor subclone may possess a Darwinian
advantage in its ability to survive the stresses of hypoxia and
cytotoxic chemotherapy,13 or it may harbor a subclone with a
mutation that renders the tumor resistant to targeted molecular
therapy. CRC is considered to be a highly heterogeneous disease,
with mounting evidence revealing various genetic aberrations in
both colon and rectal tumors.24

Alissa Greenbaum et al
Figure 1 Acquired COSMIC Mutations in Rectal Cancer Samples. Frequencies of Occurrence (A) and Observed Variant Allele
Frequencies (B) for Somatic Mutations Listed in COSMIC Database

Abbreviation: COSMIC ¼ Catalog of Somatic Mutations in Cancer.
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Figure 2 Distribution of COSMIC Mutations in Rectal Cancer Samples. Heat Map Shows Presence of Mutations Listed in COSMIC
Database in Rectal Cancer Samples Analyzed. Samples at Left (Black) Showed Complete or Moderate Response to nCRT;
Samples at Right (Red) Showed Minimal or Poor Response

Abbreviations: COSMIC ¼ Catalog of Somatic Mutations in Cancer; nCRT ¼ neoadjuvant chemoradiotherapy.

The MATH score offers a global assessment of tumor heterogeneity, compared to the single-gene assessments currently used in
CRC. KRAS mutations are present in nearly 40% of CRC tumors25
and are known to drive resistance to anti-EGFR monoclonal antibody treatment. Patients with KRAS wild-type tumors should
beneﬁt from anti-EGFR therapy, though nearly 35% of such tumors will not respond to treatment.25,26 It has been hypothesized
that this treatment resistance is the result of the presence of subclones possessing KRAS mutations, many times with concurrent
BRAF and PIK3CA mutations. The current standard method of
tumor biopsy in both clinical and research settings cannot detect the
presence or extent of such genetic heterogeneity, as only one area of
the tumor is sampled. In fact, nearly one third of CRC tumors
demonstrate ITH by analyzing RAS mutations in multiple tumor
areas.27 Similar rates of intertumoral heterogeneity (39%) are seen
between primary tumors and either lymph node or distant metastases.27 While detection of mutations such as KRAS has helped to
guide targeted molecular therapy, the extreme degree of genetic
heterogeneity in CRC presents a major challenge to precision
medicine.28
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Predicting which patients have disease that will respond to nCRT
holds important clinical implications in rectal cancer. Complete
pathologic response, deﬁned as ypT0N0M0 after nCRT and total
mesorectal excision, is seen in 15% to 20% of patients with rectal
cancer. Complete response is associated with decreased local
recurrence and improved OS.7-9 Conversely, patients with disease
with little or no response to nCRT experience poorer outcomes and
survival. Although high ITH is known to contribute to cytotoxic
and targeted molecular therapy resistance in CRC, breast, esophageal, and lung cancers,29,30 no studies to date have directly examined the relationship of rectal cancer tumor heterogeneity and
response to nCRT. By stratifying the biologic proﬁles of locally
advanced rectal cancer, providers could have the ability to discuss an
individual patient’s prognosis. Recommendations could be tailored
toward more aggressive adjuvant treatment or toward observation
according to their predicted response to nCRT.
The MATH score, originally developed in 2013 and studied in
head and neck squamous-cell carcinoma,12 now presents a novel
potential biomarker in CRC. We previously demonstrated that
higher MATH scores are associated with more advanced stages of

Alissa Greenbaum et al
Figure 3 Tumor Heterogeneity and MATH Scores. Observed VAFs Are Displayed as Histograms (Top, A and B) or Plots of VAF Versus
Read Depth (Bottom, C and D) for Samples 16 (Left, MATH [ 6.62) or 44 (Right, MATH [ 27.95). Note Spread in Observed
VAF in Sample With Higher MATH Score

Abbreviations: MATH ¼ mutant-allele tumor heterogeneity; VAF ¼ variant allele frequency.

disease and increased metastatic capability.17 One previous study to
date has speciﬁcally applied MATH scores to rectal cancer.18 Nextgeneration sequencing of 2 to 3 separate areas of 6 rectal tumors
found that although all patients demonstrated heterogeneity, the
degree varied signiﬁcantly. Our study is consistent with these
ﬁndings, with the added correlation of tumor heterogeneity to
treatment response. The MATH score offers a promising method to
identify patients at high risk of treatment failure, both in practice
and in clinical trial settings. It should be mentioned, however, that
although computation of the MATH score may allow for patient
stratiﬁcation and prediction of nCRT response, it does not address
the complex issue of how to improve treatment for patients with
increased tumor heterogeneity.
One limitation of this study is its small sample size of 21 rectal
tumors. However, this is the largest analysis using MATH scores in

rectal cancer to date, and the comparison of MATH scores by
nCRT response categories was striking enough to yield signiﬁcant
results. Second, the rectal cancer samples and MATH scores were
retrospectively obtained. A prospectively designed study must be
conducted to further investigate MATH score as a clinical
biomarker. Third, DNA sampling and analysis was performed from
one area of the tumor. Although future studies will sample multiple
tumor areas, whole-tumor sequencing is not yet possible. Future
studies in rectal cancer should also examine MATH scores in relation to oncologic outcome data including OS, disease-free survival,
and local recurrence.
Tumor heterogeneity presents a challenge to the developing ﬁeld
of precision oncology. In this pilot study, we applied a novel bioinformatics approach, the MATH score, to quantitatively measure
tumor genetic heterogeneity in locally advanced rectal cancer.
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Figure 4 MATH Scores Correlate With Poor Response to nCRT. Box Plots Compare MATH Scores for Patients Who Demonstrated
Complete Versus Poor Response to nCRT (A), Complete Response Versus Moderate, Minimal, or Poor Response (B), and
Complete or Moderate Versus Minimal or Poor Response (C). There Was No Correlation Between MATH Scores and Presence
of Mutations in APC Gene (D)

Abbreviations: MATH ¼ mutant-allele tumor heterogeneity; nCRT ¼ neoadjuvant chemoradiotherapy.

Higher MATH scores were associated with poorer response to
nCRT. MATH scores present a potential biomarker to predict
nCRT response in rectal cancer in both clinical and research
settings.

Conclusion
The MATH score is a quantitative measure of tumor heterogeneity. This technique does not rely on a single gene mutation or a
unique signaling pathway. The MATH score uses the entire 400þ
gene data set to look at the shape of the data. MATH scores
generated from pretreatment rectal cancer biopsy samples correlate
with response to nCRT. Thus, knowing a patient’s MATH score
may allow for customizing treatment protocols.
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Clinical Practice Points
 Rectal cancer remains a leading cause of cancer-related morbidity

and mortality.
 Locally advanced tumors are treated with chemotherapy and

radiotherapy before surgical resection. This approach leads to
decreased local recurrence rates, perioperative complications, and
possibly increases the rate of sphincter preservation. Currently it
is not known which patients have disease that will have a
favorable response to chemoradiation.
 By using next-generation sequencing techniques, we found that
the quantitative MATH score, a reﬂection of tumor heterogeneity, correlates with response to neoadjuvant chemoradiation
treatment.

Alissa Greenbaum et al
 Higher MATH scores correlate with a poorer response to neo-

adjuvant chemoradiation. This is important information to
know, as patients with disease with less favorable response fare
worse compared to patients with disease with a good response to
such treatments.
 Knowing a patient’s MATH score and thus the degree of heterogeneity may allow for a more practical and economic surveillance strategy, and possibly better personally designed
treatment algorithms.
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